Objectives-To test the effectiveness of and tolerance to interferon-alpha 2b (INFa2b) in association with plasma exchanges for the treatment of polyarteritis nodosa (PAN) related to hepatitis B virus (HBV). [334][335][336][337] Polyarteritis nodosa (PAN) is a well-known form of necrotising angiitis. The association of PAN with hepatitis B virus (HBV) was described in 19703 and has been confirmed by many previous reports.2 3 In our experience,46 the evolution of PAN and HBV infection were usually dissociated in patients with HBVrelated PAN treated with steroids and immunosuppressive drugs such as cyclophosphamide. Most of the patients who recovered from PAN had chronic HBV infections and in some cases we observed a progression to cirrhosis. In a previous study,7 we reported the effectiveness of the association of a short term steroid treatment followed by the combination of vidarabine (Vira A), plasma exchanges in the treatment of HBV-related PAN. The purpose of this study was to test a new antiviral agent, INFa2b, in association with plasma exchanges as the first-line treatment of HBV-related PAN.
(HBV).
Methods-A prospective, non blinded, multicentre trial was carried out in which patients with multisystemic HBV-related PAN were included. Each patient received the association of INFa2b and plasma exchanges. The end point of the study was control of the disease (recovery or remission) or death. Results-Six patients were included in the study. Each patient had histopathological or arteriographic evidence of vasculitis and was infected with actively replicating HBV. All patients were alive at the end of the study and no longer presented clinical or laboratory evidence of systemic vasculitis. HBeAg/anti-HBeAb seroconversion was observed in four patients (66.6%) and HBsAg/anti-HBsAb in 3/6 (50°/0). Two patients are still being treated with INFa2b because of chronic active hepatitis. Conclusions-It is considered that this new therapeutic approach to HBV-related PAN effectively cured systemic vasculitis and was associated with control of HBV infections. Antiviral therapy may have a role to play as the first line treatment regime ofvirus-induced vasculitis.
(Ann Rheum Dis 1994; 53: [334] [335] [336] [337] Polyarteritis nodosa (PAN) is a well-known form of necrotising angiitis. The association of PAN with hepatitis B virus (HBV) was described in 19703 and has been confirmed by many previous reports.2 3 In our experience,46 the evolution of PAN and HBV infection were usually dissociated in patients with HBVrelated PAN treated with steroids and immunosuppressive drugs such as cyclophosphamide. Most of the patients who recovered from PAN had chronic HBV infections and in some cases we observed a progression to cirrhosis. In a previous study,7 we reported the effectiveness of the association of a short term steroid treatment followed by the combination of vidarabine (Vira A), plasma exchanges in the treatment of HBV-related PAN. The purpose of this study was to test a new antiviral agent, INFa2b, in association with plasma exchanges as the first-line treatment of HBV-related PAN.
Patients and methods

PATIENTS
Criteria for entry into the study were similar to those previously described.7 All patients had PAN with multiple system involvement; histological or angiographic evidence of vascular lesions indicative of a diagnosis of vasculitis; HBV infection with active viral replication. Previous treatment with steroids, cyclophosphamide and Vira A were considered exclusion criteria. Patients were consecutively enrolled in the trial. Recruitment began in January 1988. The end point of the study was control of the disease (recovery and remission, as defined below) or the patient's death. The study protocol was approved by the Biomedical Ethics Committee of the University of Paris-Nord. TREATMENT Every patient had plasma exchanges, which were started just after the patient's inclusion in the study. Each patient had nine to 12 plasma exchanges during the first three weeks of treatment with INFa2b. During this period, the number of plasma exchanges depended on vascular access and the level of clotting factors before plasma exchanges. After this period, plasma exchanges were performed two or three times a week, depending on the clinical results observed, and then stopped. The amount of plasma scheduled to be exchanged during each session was 60 ml/kg of body weight. The replacement fluid consisted of 500 ml of fluid gelatin and 4% albumin.
SEROLOGICAL ASSAYS
Patients' sera were tested with commercial radioimmunoassays (Abbott) for the presence of HBsAg, anti-HBsAb and anti-HBcAb and, when HBsAg positive, for HBeAg and antiHBeAb. The presence of HBV DNA in the sera was assayed using a spot hybridisation technique and HBV DNA polymerase as previously described. The clinical manifestations of PAN in the six study patients are summarised in the table. Of the six patients, four were men and two were women; their mean (SD) age at inclusion was 56-5 (14-1) years (range: 36-72 years). In four of six patients it was possible to determine the origin of the contamination with HBV: blood transfusion in patient 6; homosexual contact with serum HBsAg-positive partners (in cases 1 and 3); dental treatments were the only suspected risk factor in patient 4. Three patients presented clinical signs of acute viral hepatitis before developing PAN within 15 days, one and 37 months (respectively cases 1, 4 and 6).
Histopathological or angiographic evidence of vasculitis was found in all six patients. patients were alive at the end of the study and had recovered completely from PAN; four of them had recovered from HBV as well and the remaining two are still being treated with lNFa2b because of chronic active hepatitis but do not present any symptoms of PAN. Sequelae of polyarteritis nodosa were present in three patients. One is handicapped by peripheral neuropathy, one (case 6) by renal failure (serum creatinine: 2-4 mg/dl) and one by hypertension requiring treatment with a converting enzyme inhibitor (case 3).
Discussion
Hepatitis B virus is an aetiological factor of polyarteritis nodosa' 210 and it has been suggested that circulating hepatitis B Ag/Ab immune complexes have an important role in the pathogenesis of vasculitic lesions." On theoretical grounds, the existence of a chronic HBV infection with a high level of virus replication should require a specific approach because steroids are known to enhance viral replication, favour the exacerbation of chronic hepatitis'2 and ultimately the progression towards liver cirrhosis. We proposed a new therapeutic sequence to obtain the following effects: initial administration of steroids to rapidly control the most severe, lifethreatening manifestations of polyarteritis nodosa which are common during the first weeks of the disease; rapid discontinuation of steroids to Although only a small number of patients has been included in the study, the therapeutic results obtained are promising. All the patients recovered completely from PAN and are still alive at the end of the study. The combination of INFa2b and plasma exchanges is well tolerated by patients and only minor side effects were observed. HBeAg/anti-HBeAb seroconversion was observed in four patients (666/6%) and HBsAg/anti-HBsAb seroconversion occurred in three (50%). Our results lead us to think that antiviral therapy will have a role to play in the treatment of virus induced vascular disease and HBV-related PAN, as recently described for cryglobulinemia associated with hepatitis C virus. ' 
